Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

Julio García-Suárez*
Hematology Department, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain

Javier de la Cruz*
Research Institute imas12, University Hospital 12 de Octubre, Madrid, SAMID-ISCIII, Spain

Ángel Cedillo
Asociación Madrileña de Hematología y Hemoterapia (AMHH), Madrid, Spain

Pilar Llamas
Hematology Department, University Hospital Fundación Jiménez Díaz, Madrid, Spain

Rafael Duarte
Hematology Department, University Hospital Puerta de Hierro Majadahonda, Madrid, Spain

Víctor Jiménez-Yuste
Hematology Department, University Hospital La Paz, Madrid, Spain

José Ángel Hernández-Rivas
Hematology Department, University Hospital Infanta Leonor, Madrid, Spain

Rodrigo Gil-Manso
Hematology Department, Hospital 12 de Octubre, imas12, Complutense University, CNIO-ISCIII, CIBERONC, Madrid, Spain

Mi Kwon
Hematology Department, University General Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Department of Medicine, Complutense University, Madrid, Spain

Pedro Sánchez-Godoy
Hematology Department, University Hospital Severo Ochoa, Madrid, Spain

Pilar Martínez-Barranco
Hematology Department, University Hospital Fundación Alcorcón, Madrid, Spain

Blanca Colás-Lahuerta
Hematology Department, University Hospital Fundación Alcorcón, Madrid, Spain

Pilar Herrera
Hematology Department, University Hospital Ramón y Cajal, Madrid, Spain

Laurentino Benito-Parra
Hematology Department, University Hospital Getafe, Madrid, Spain

Adrián Alegre
Hematology Department, University Hospital La Princesa, Madrid, Spain

Alberto Velasco
Hematology Department, University Hospital Rey Juan Carlos, Móstoles, Madrid, Spain

Arturo Matilla
Hematology Department, University Hospital Central de la Defensa Gómez Ulla, Madrid, Spain

María Concepción Aláez-Usón
Hematology Department, University Hospital HLA Moncloa, Madrid, Spain

Rafael Martos-Martínez
Hematology Department, University Hospital Villalba, Villalba, Madrid, Spain

Carmen Martínez-Chamorro
Hematology Department, University Hospital Quirónsalud, Pozuelo de Alarcón, Madrid, Spain

Keina Susana-Quiroz
Hematology Department, University Hospital Móstoles, Madrid, Spain
Abstract

Background Patients with cancer have been shown to have a higher risk of clinical severity and mortality compared to non-cancer patients with COVID-19. Patients with hematologic malignancies typically are known to have higher levels of immunosuppression and may develop more severe respiratory viral infections than patients with solid tumors. Data on COVID-19 in patients with hematologic malignancies are limited. Here we characterise disease severity and mortality, and evaluate potential prognostic factors for mortality.

Methods In this population-based registry study, we collected de-identified data on clinical characteristics, treatment and outcomes in adult patients with hematologic malignancies and confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection within the Madrid region of Spain. Our case series included all patients admitted to 22 regional health service hospitals and 5 private healthcare centres between February 28 and May 25, 2020. The primary study outcome was all-cause mortality. We assessed the association between mortality and potential prognostic factors using Cox regression analyses adjusted for age, sex, comorbidities, hematologic malignancy and recent active cancer therapy.

Results Of 833 patients reported, 697 were included in the analyses. Median age was 72 years (IQR 60–79), 413 (60%) patients were male, and 479 (69%) and 218 (31%) had lymphoid and myeloid malignancies, respectively. Clinical severity of COVID-19 was severe/critical in 429 (62%) patients. At data cutoff, 230 (33%) patients had died. Age ≥60 years (hazard ratios 3·17–10·1 vs <50 years), >2 comorbidities (1·41 vs ≤2), acute myeloid leukemia (2·22 vs non-Hodgkin lymphoma) and active antineoplastic treatment with monoclonal antibodies (2·02) or conventional chemotherapy (1·50 vs no active therapy) were associated with increased mortality. Conversely, Ph-negative myeloproliferative neoplasms (0·33) and active treatment with hypomethylating agents (0·47) were associated with lower mortality. Overall, 574 (82%) patients received antiviral therapy. Mortality with severe/critical COVID-19 was higher with no therapy vs any antiviral combination therapy (2·20).

Conclusions In this series of patients with hematologic malignancies and COVID-19, mortality was associated with higher age, more comorbidities, type of hematological malignancy and type of antineoplastic therapy. Further studies and long-term follow-up are required to validate these criteria for risk-stratification.

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) have resulted in a World Health Organization (WHO)-classified pandemic. Most patients with SARS-CoV-2 infection are asymptomatic or exhibit mild-to-moderate symptoms, but approximately 15% progress to severe pneumonia, and 5% require intensive care unit (ICU) management due to acute respiratory distress syndrome, septic shock, and/or multiple organ failure. As of July 29, 2020, 16,708,920 cases of COVID-19 have been reported, including 660,123 deaths. Case fatality is reported at 3.95%, but this varies widely by location.

Poor-risk factors for outcome in COVID-19 patients include old age, hypertension, cardiovascular disease, and diabetes. Cancer patients also appear to have a worse prognosis. A meta-analysis found that cancer prevalence in people with COVID-19 was 2%. More importantly, patients with cancer had a higher risk of severe events (admission to an ICU requiring invasive ventilation, or death) compared to those without cancer (11% to 39% vs 5.8% to 7.6%). A large-scale study using UK Coronavirus Cancer Monitoring Project data gave consistent findings.

Patients with hematologic malignancies usually have higher levels of immunosuppression and may develop more severe respiratory viral infections than patients with solid tumors. In Europe and the United States, hematologic malignancies comprise the fourth most common cancer site. The use of new antineoplastic agents, particularly novel targeted therapies, has improved overall survival. However, these therapies have side-effects on humoral and cell-mediated immunity, increasing the risk of infections caused by viral agents. To date, few data are available on COVID-19 in patients with hematologic malignancies. Reported studies have focused on hospitalized patients. One showed very high mortality (40% at 1 month) among 25 patients in France. A second suggested that hospitalized patients with hematologic malignancies have a higher mortality rate than patients without hematologic malignancies (62% vs 8%). However, these were small patient series; the clinical impact of COVID-19 in this population remains unclear. Therefore, real-time collection, analysis, and dissemination of data about COVID-19 in patients with hematologic malignancies and their outcomes is needed. Meanwhile, impactful decisions are being suggested on the basis of expert opinion.
The Madrid region was the epicenter of Spain’s COVID-19 crisis. The first cases were declared in Spain on January 31 and in the Madrid region on February 25, 2020. As of 29 July, 78,807 patients had been diagnosed with COVID-19 and 15,199 fatalities reported in the Madrid region.(18) We therefore considered it critical to collect data on clinical characteristics, treatment received, and outcomes in patients with hematologic malignancies within a defined geographical area with high excess mortality in order to understand the epidemiology and outcomes of COVID-19 in this vulnerable population. We aimed to identify independent prognostic factors of mortality that could support recommendations for managing patients with hematologic malignancies in healthcare emergency situations such as the COVID-19 pandemic.

Methods

Study design and participants

This was a multicenter, registry-based study with prospective data collection sponsored by the Madrid Society of Hematology (Asociación Madrileña de Hematología y Hemoterapia, AMHH). AHMM established the registry on March 13 by contacting all members to register patients with hematologic malignancies who had microbiological confirmation of SARS-CoV-2 infection. Healthcare for patients with hematologic malignancies in the Madrid region is provided at 26 hospitals affiliated with the Madrid regional health service (Servicio Madrileño de Salud, SERMAS), covering a population of 6.6 million inhabitants. Additionally, patients are seen at six private non-SERMAS-affiliated healthcare centers. This case series included consecutive patients with hematologic malignancies aged ≥18 years who received a confirmed diagnosis of COVID-19 in the emergency departments, hospital wards (patients infected while hospitalized), or outpatient clinics of these Madrid hospitals up to May 25, 2020. Clinical specimens for diagnosis confirmation were obtained by nasopharyngeal swab collection in accordance with Spanish disease control and prevention guidelines. Samples were processed at local microbiology laboratories, and SARS-CoV-2 one-step real-time reverse transcriptase PCR diagnostic assay was performed.(19)

The study was approved by the Institutional Review Board (IRB) of University Hospital 12 de Octubre (n 20/189) and then by the IRBs of all participating centers. Written informed consent was waived in light of the urgent need to collect and report data. The study was performed in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines.

Procedures

Data were prospectively extracted locally from electronic health records by hospital hematology department study coordinators and uploaded to a secure web platform (HEMATO-MADRID COVID-19), which utilized REDCap data capture tools and was supported by AMHH. Anonymized data were centrally processed by a coordinating team at AMHH and checked for duplicates. Clinical management decisions were made according to local protocols at each center; national guidelines for COVID-19 treatment issued by the Spanish Ministry of Health, National Health System, and National Medicine Agency were widely implemented. Decisions about hospital/ICU admissions were made locally based on daily updated criteria during the healthcare emergency period.

Potential prognostic factors were collected including pre-infection patient characteristics (age, sex, comorbidities, type of hematologic malignancy and therapy), COVID-19 clinical severity, treatments, and care setting. ‘Active antineoplastic treatment’ was defined as having received anticancer therapy within 30 days prior to COVID-19 diagnosis. Therapies were classified as ‘conventional chemotherapy’, ‘low-intensity chemotherapy’, hypomethylating agents, monoclonal antibodies, immunomodulatory drugs, ‘molecular targeted therapies’, or supportive care (Table 1). COVID-19 severity classification followed WHO guidelines.(20) No data on symptoms, laboratory findings, respiratory support, or viral kinetics were available for analyses as standardization was not achieved.

Outcomes
Participant vital status (death from any cause vs alive) was the main study outcome. Study centers could update patient status through to data cut-off (May 25, 2020). Observation time for individual patients was calculated from date of SARS-CoV-2 positivity to date of death or last information update.

**Statistical analysis**

Potential pre-infection prognostic factors of mortality were analyzed in three steps: unadjusted, partially adjusted, and adjusted analyses. The associations between mortality and therapies received for COVID-19 were determined according to clinical severity (dichotomized as mild/moderate or severe/critical). Hazard ratios (HR) and 95% confidence intervals (CI) were estimated with Cox regression analyses. Variables included in the models were prespecified and restricted in number to limit model overfitting. Analyses were generated using SAS/STAT software, Version 9.4, SAS Institute Inc.

**Results**

Of 833 patients reported to the HEMATO-MADRID COVID-19 registry by 27/32 healthcare providers, 697 were included in the present analyses (Figure 1). The earliest PCR confirmation date in registered patients was February 28, 2020; during the 12-week reporting period, 5% of cases were reported in the 2 weeks prior to the start of lockdown, 75% in the following 4 weeks, and the remaining 20% in the last 6 weeks.

Of the 697 patients, 479 (69%) had a lymphoid malignancy, including 187 (27%) with non-Hodgkin lymphoma and 137 (20%) with multiple myeloma, and 218 (31%) had a myeloid malignancy, including 78 (11%) with myelodysplastic syndrome, 61 (9%) with acute myeloid leukemia (AML) and 63 (9%) with Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs) (Table 1). Overall median age of patients was 72 years (IQR 60–79) and 413/690 (60%) were male. Comorbidities were present in 80% of patients, the commonest being hypertension (40%), cardiac disease (20%), and diabetes (17%) (Table 1).

In total, 405 (59%) patients were receiving active antineoplastic treatment, including at least 75% of patients with multiple myeloma, AML, chronic myeloid leukemia (CML), and Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs) (Table 1). The rate was 31% in patients with chronic lymphocytic leukemia or myelodysplastic syndrome. Overall, 127 (18%) patients were receiving conventional chemotherapy, 81 (12%) molecular targeted therapies, 44 (6%) monoclonal antibodies, and 45 (6%) immunomodulatory drugs. Among 79 (12%) patients with history of hematopoietic stem cell transplantation (HSCT), 52 had received an autologous and 27 an allogeneic transplant; median age was 61 years (IQR 53-63), and median time since transplantation was 22 months (IQR 8-56).

COVID-19 clinical severity was classified as severe/critical in 62% of patients, moderate in 23%, and mild in 15% (Table 2); 46% of transplant recipients had severe/critical disease. Patients with severe/critical disease were older and more likely (51%/22%) to have ≥3 comorbidities than those with mild COVID-19 (9%) (Table 2). Overall, 87% of patients required hospitalization, and 13% received ambulatory management (Table 1); 55 (8%) were admitted to an ICU (Table 2), most of whom had organ function damage, including 40/55 (73%) with acute respiratory distress syndrome and 2 (4%) with sepsis. Median age of ICU-admitted patients was 61 years (IQR 56-70).

230 of 697 (33%) patients died, of whom 221 (96%) were hospitalized; 28/55 (51%) ICU-admitted patients died. Death was attributable to COVID-19 in 202 (88%) patients. Median time from confirmation of COVID-19 to death was 9 days (IQR 5-18). Median follow-up time for survivors was 43 days (IQR 32-53). Clinically relevant variables associated with increased mortality after multivariable adjustment (Table 3) were increasing age >60 years, >2 comorbidities (HR 1.4, 95% CI 1.05-1.90, vs ≤2 comorbidities), AML (vs non-Hodgkin lymphoma), and active antineoplastic treatment with monoclonal antibodies vs no active therapy; there was 50% increased mortality in patients receiving conventional chemotherapy vs no active therapy (HR 1.50). Prognostic variables associated with lower mortality included Ph-negative MPNs (HR 0.33 vs non-Hodgkin lymphoma) and active treatment with hypomethylating agents (HR 0.47 vs no active treatment). Mortality rate among patients who underwent transplantation was 18%.
Overall, 574 (82%) patients received antiviral therapy (with β-interferon in 50 patients as an immunity booster), the most common being hydroxychloroquine in combination with antiretrovirals, azithromycin, or both (Table 4). Additionally, 346 (50%), 318 (46%), and 132 (19%) patients received empirical antibiotics, systemic corticosteroids (mainly methylprednisolone and prednisone), and off-label tocilizumab, respectively. Patients with severe/critical COVID-19 who did not receive antiviral therapy had a higher risk of death than patients receiving any antiviral combination therapy (HR 2.20, 95% CI 1.44-3.35) on multivariable analysis (Table 4). Mortality in patients treated with tocilizumab differed according to clinical severity of COVID-19 (test for strata homogeneity, p<0.0001), with a higher risk in patients with mild/moderate COVID-19 treated vs not treated with tocilizumab (HR 5.94).

Discussion

To our knowledge, this is the first large-scale case series describing the epidemiology and outcome of COVID-19 in patients with hematologic malignancies. To date, only small case series in this setting have been reported(14, 15, 21, 22) in mainly hospitalized patients, whereas our study included both inpatients and outpatients. Our findings show that patients with hematologic malignancies and COVID-19 have 3-4-fold higher rates of severe/critical disease (62% vs 15%) and mortality (33% vs 10%) compared to COVID-19 cases in the general population.(23-25) Clinical severity of COVID-19 was worse and mortality rates were higher among older patients and those with a greater number of comorbidities, and varied by type of hematologic malignancy and active antineoplastic treatment. Rates of severe/critical COVID-19 and mortality in our study were higher than reported in patients with solid tumors (26-43% and 13-28%; respectively).(9)

Despite the high societal impact of COVID-19 in Spain, the ENE-COVID nation-wide, population-based study reported a SARS-CoV-2 seroprevalence of 11.5% for the Madrid region,(26) which is clearly insufficient to provide herd immunity. Together with our study, these findings have important policy implications, including the need for increased surveillance for SARS-CoV-2 in patients with hematologic malignancies.

Among the strengths of this study are the prospective and comprehensive collection of clinical and outcome data, and the use of multivariable analysis to identify independent risk factors for death. Our patient series is highly representative of this population as, in Spain, healthcare for all patients with hematologic malignancies is centralized in hospitals. Furthermore, all hospitals in the Madrid region were under the governance of the Madrid Health System authorities and were following the guidelines of the Spanish Health Minister. We therefore believe that the mortality rate in our study reflects the true mortality rate in patients with hematologic malignancies and COVID-19 that contacted the healthcare system during the growth phase of the pandemic. Another strength was the selection of a restricted number of prognostic factors based on clinical features for determining associations with mortality rate. These factors could be utilized in a prognostic model to stratify patients with hematologic malignancies and to implement preventive strategies for future healthcare crises.

Key risk factors for clinical severity and mortality previously reported in the general population (e.g. older age, higher number of comorbidities) were validated in our study. Notably, the median age of patients in our series was higher than in the general population with COVID-19 (72 vs 60 years), with 32% of cases occurring in patients aged 70-79 years; in the general population, COVID-19 cases were more uniformly distributed across age groups.(23) Additionally, our findings highlight that the type of hematologic malignancy were associated with COVID-19 mortality. Our study showed relatively higher mortality rates in patients with AML (44%) and myelodysplastic syndrome (42%) and relatively lower rates in patients with Ph-negative MPNs (19%) and CML (13%), consistent with a Chinese study of 5 patients with CML receiving tyrosine kinase inhibitor (TKI) therapy.(27)

The differential outcomes from COVID-19 between patients with different hematologic malignancies could be associated with multiple factors. On multivariate analysis, we found that type of active antineoplastic treatment appeared associated with mortality from COVID-19. Patients receiving monoclonal antibody-based therapy had a significantly greater (HR 2.02) risk of death vs those not receiving active antineoplastic treatment, while those receiving active conventional chemotherapy were 50% more likely to die from COVID-19. By contrast, there was a significant 53% lower mortality among patients receiving hypomethylating agents.
The association between low-intensity chemotherapy and lower COVID-19 mortality in our partially adjusted analysis could be in part because nearly half of patients with Ph-negative MPNs were receiving this chemotherapy. Interestingly, acknowledging that the number of patients with CML was low, 88% were receiving molecular targeted therapies (TKI therapy), and mortality rate was only 13%. Kinase inhibitor-targeted therapy was demonstrated to block dissemination of SARS-CoV and Middle East respiratory syndrome coronavirus and is being investigated as a potential therapeutic approach against SARS-CoV-2. Our findings suggest that patients with CML may even garner some protection against poor outcomes with COVID-19 due to their TKI therapy; discontinuing such therapy out of fear of COVID-19 might not be warranted.

The clinical characteristics, management, and outcome of COVID-19 in patients undergoing HSCT remain unknown; guidelines are being generated by various organisations. Our real-world data showed a mortality rate of 18%. However, this figure should be interpreted with caution as both type of transplant and time from transplant (IQR 8-56 months) were heterogeneous. Our data suggest that life-saving transplantation should not be delayed in patients with hematologic malignancies, although close monitoring is of paramount importance.

Although the majority of the 230 deaths in our case series occurred during hospitalization, only 55 (8%) patients were admitted to an ICU. This rate is consistent with reports from the UK and USA in which the incidence of ICU admission among patients with all types of cancer and COVID-19 was 6-14%. We were not able to determine from our dataset whether a diagnosis of a hematologic malignancy decreases a patient’s chances of accessing such intensive support, for example due to equipment and/or personnel shortages. In our cohort, overall mortality rate in patients admitted to an ICU was 51%, suggesting that many patients with hematologic malignancy can survive COVID-19 and require equivalent access to ICU care.

There are currently no approved treatment options for patients with COVID-19 in Europe, and no clear recommendations can be made regarding specific therapies due to limited data and unknown risk:benefit profiles. Even fewer such data are available for patients with hematologic malignancies. Our study is the first in which the effect of COVID-19 treatments has been studied in such patients with different degrees of clinical severity of COVID-19. Interestingly, our findings showed that in patients with severe/critical COVID-19, not receiving any antiviral therapy was associated with higher mortality than being treated with any antiviral combination therapy. However, this was a non-randomized study and residual confounding by indication may explain this finding. These data provide a rationale for including patients with hematologic malignancies in investigational strategies of antiviral therapy. Notably, we also observed that the mortality rate in patients with mild/moderate COVID-19 was nearly 6-fold higher among these treated with, vs not receiving, tocilizumab. As treatment experience improved, clinicians increasingly prescribed tocilizumab for patients with non-severe COVID-19 who had evolving cytokine release syndrome. Therefore, the increased mortality rate in this population might not be caused directly by tocilizumab. Further, tocilizumab was not associated with any benefit in patients with severe/critical COVID-19.

Limitations

Our study has some limitations. First, this was primarily an observational cohort study designed for rapid patient accrual during the nonlinear growth phase of the COVID-19 outbreak. For this reason, our study introduces uncertainty into the exact timing of therapeutic intervals, as required to meet IRB regulatory requirements. Second, although to the best of our knowledge we included all patients with hematologic malignancies and COVID-19, the true number of such patients might have been higher because of the low rate of testing or misdiagnoses at the beginning of the pandemic and including only patients who contacted the healthcare system. More data on the prevalence and outcomes of COVID-19 in asymptomatic patients with hematologic malignancies could emerge as hospital systems implement more comprehensive testing of all patients seeking care. Third, data on clinical symptoms, laboratory findings, and disease status were missing. Finally, our case series incorporates a heterogeneous patient population with multiple different hematologic malignancies; further studies in patients with specific malignancies are needed, as it is possible that type of malignancy and disease status may affect the clinical course of COVID-19. Nevertheless, our study included a large number of patients with some malignancies, which could overcome in part this perceived limitation.
Conclusions

In conclusion, our findings support the vulnerability of patients with hematologic malignancies in the COVID-19 pandemic and provide several important considerations for clinical care. In addition to the previously determined risk factors of older age and multiple comorbidities, patients with AML and those currently receiving or who have recently received antineoplastic therapy with conventional/intensive cytotoxic chemotherapy or with monoclonal antibodies are at increased risk of death. By contrast, we found evidence that active treatment with hypomethylating agents may be associated with more favorable outcomes. The higher mortality in patients with hematologic malignancies and severe/critical COVID-19 who did not receive antiviral therapy provides the rationale for including these patients in investigational strategies. Further studies and long-term follow-up are required to validate these criteria for risk-stratifying patients with hematologic malignancies in a future healthcare crisis and for defining appropriate timing and types of antineoplastic treatments.

List Of Abbreviations

SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2;
COVID-19, Coronavirus disease 2019;
WHO, World Health Organization;
ICU, Intensive Care Unit;
AMHH, Madrid Society of Hematology - Asociación Madrileña de Hematología y Hemoterapia;
SERMAS, Madrid Regional Health Service - Servicio Madrileño de Salud;
IRB, Institutional Review Board
IQR, Interquartile range
HR, Hazard Ratio
CI, confidence interval
AML, Acute Myeloid Leukemia
CLL, Chronic Lymphocytic Leukemia
Ph, Philadelphia chromosome
CML, chronic myeloid leukemia
MPN, myeloproliferative neoplasms
HSCT, hematopoietic stem cell transplantation

Declarations

Ethics approval and consent to participate

The study was approved by the Institutional Review Board (IRB) of University Hospital 12 de Octubre (n#20/189) and then by the IRBs of all participating centres. Written informed consent was waived in light of the urgent need to collect and report data.

Consent for publication

Not applicable
Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

Funding source: Fundación Madrileña de Hematología y Hemoterapia. This project was partly performed with a grant “Marcos Fernández-Vistare” from the Fundación Leucemia y Linfoma.

Role of the funding source: The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. JG-S, JdlC, JLD-M and JM-L had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Authors' contributions

Study design: JG-S, JdlC, JLD-M and JM-L; Study investigators: AC, PL; RD, VJ-Y, JAH-R, RG-M, MK, PS-G, PM-B, BC-L, PH, LB-P, AA, AV, AM, MCA-U, RM-M, CM-Ch, KS-Q, JDdC, AdIF, RH, AP, EG, JP-Q, ER, AA, JG-M, LNM-B, MC, IG-G, MCV-A, SV, MG-R, PE-M, JL-J, CE-E, and JO-M; Data analysis: JdlC; Data interpretation: JG-S, JdlC, JLD-M and JM-L; Manuscript preparation: JG-S, JdlC, and JM-L; Manuscript review and revisions: JG-S, JdlC, and JM-L; Final approval of manuscript: All authors.

Acknowledgements

We wish to thank all the patients included in this study and also all healthcare staff and the entire leadership team of the participating hospitals.

The work is hosted by Asociación Madrileña de Hematología y Hemoterapia (AMHH).

The authors gratefully acknowledge Steve Hill of FireKite, an Ashfield company, part of UDG Healthcare plc, for editorial assistance in the preparation of the manuscript.

Collaborating authors:

Cristina Serí-Merino (Hematology Department, University Hospital Central de la Defensa Gómez Ulla, Madrid, Spain); Keina Queiroz-Cervantes (Hematology Department, University Hospital Móstoles, Madrid, Spain); Mónica Estévez Fernandez (Hematology Department, MD Anderson Cancer Center Madrid, Spain); María-José Peñalva-Moreno (Hematology Department, University Hospital Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain); Daniel Naya-Errea; Laura Bermejo-Martínez (Hematology Department, University Hospital Infanta Elena, Valdemoro, Madrid, Spain); Laura Llorente- González (Hematology Department, University Hospital HM Sanchinarro, Madrid, Spain).

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.

2. World Health Organization. Timeline of WHO's response to COVID-19. 2020 15/07/2020. Available from: https://www.who.int/news-room/detail/29-06-2020-covidtimeline.
3. European Centre for Disease Prevention and Control. COVID-19 situation update worldwide. 2020 15/07/2020. Available from: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases.

4. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-5.

5. Meng Y, Lu W, Guo E, Liu J, Yang B, Wu P, et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis. J Hematol Oncol. 2020;13(1):75.

6. Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hematological malignancies. Ann Oncol. 2007;18 Suppl 1:i3-i8.

7. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.

8. Tang YW, Schmitz JE, Persing DH, Stratton CW. Laboratory Diagnosis of COVID-19: Current Issues and Challenges. J Clin Microbiol. 2020;58(6):doi: 10.1128/JCM.00512-20.

9. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Interim guidance. 2020 15/07/2020. Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.
10.1001/jama.2020.648.

26. Pollan M, Perez-Gomez B, Pastor-Barriuso R, Oteo J, Hernan MA, Perez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020:doi: 10.1016/S0140-6736(20)31483-5.

27. Li W, Wang D, Guo J, Yuan G, Yang Z, Gale RP, et al. COVID-19 in persons with chronic myeloid leukaemia. Leukemia. 2020:doi: 10.1038/s41375-020-0853-6.

28. Sisk JM, Frieman MB, Machamer CE. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J Gen Virol. 2018;99(5):619-30.

29. European Society for Blood and Marrow Transplantation (EBMT). COVID-19 and BMT. 2020 15/07/2020. Available from: https://www.ebmt.org/covid-19-and-bmt

30. Szer J, Weisdorf D, Querol S, Foeken L, Madrigal A. The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage. Bone Marrow Transplant. 2020:doi: 10.1038/s41409-020-0873-x.

31. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-18.

32. Martinez-Lopez J, Mateos M-V, Encinas C, Sureda A, Hernandez-Rivas JA, Lopez de la Guia A, et al. Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality. medRxiv [Internet]. 2020 15/07/2020. Available from: https://www.medrxiv.org/content/10.1101/2020.06.29.20142455v1.

Tables

Table 1. Characteristics and outcomes of patients with hematologic malignancies and COVID-19, according to type of malignancy
|                        | Lymphoid malignancies | Myeloid malignancies |
|------------------------|-----------------------|----------------------|
| **Patients**           | **Total**             | **NHL** | **MM** | **CLL** | **HL** | **ALL** | **MDS** | **AML** | **CML** | **Ph-MPN** |
|                        | 697 (100)             | 187 (27) | 137 (20) | 109 (15) | 33 (5) | 13 (2) | 78 (11) | 61 (9) | 16 (2) | 63 (9) |
| **Age, years**         |                       |         |         |         |         |         |         |         |         |         |
|                        |                       | 72 (60-79) | 70 (58-77) | 73 (65-79) | 73 (60-81) | 59 (45-75) | 45 (37-55) | 80 (71-86) | 65 (52-76) | 61 (48-74) | 75 (66-83) |
| **Sex**                | % shown as proportion of all patients with that malignancy |         |         |         |         |         |         |         |         |         |         |
| Female                 | 277 (40)              | 81 (44) | 56 (41) | 39 (36) | 12 (38) | 7 (54) | 27 (35) | 32 (53) | 3 (20) | 20 (32) |
| Male                   | 413 (60)              | 104 (56) | 81 (59) | 68 (64) | 20 (62) | 6 (46) | 51 (65) | 28 (47) | 12 (80) | 43 (68) |
| **Comorbidities, n**   | 2 (1-3)               | 1 (1-2) | 2 (1-3) | 1 (1-3) | 1 (1-3) | 1 (0-1) | 2 (1-3) | 1 (0-2) | 1 (0-3) | 2 (1-3) |
| Cardiac disease        | 138 (20)              | 33 (18) | 30 (22) | 20 (18) | 8 (24) | 1 (8) | 22 (28) | 7 (11) | 3 (13) | 2 (13) |
| Pulmonary disease      | 90 (13)               | 21 (11) | 20 (15) | 16 (15) | 2 (6) | 1 (8) | 14 (18) | 6 (10) | 4 (25) | 6 (10) |
| Renal disease          | 77 (11)               | 11 (6) | 32 (23) | 8 (7) | 4 (12) | 1 (8) | 9 (12) | 22 (36) | 4 (25) | 9 (14) |
| Hypertension           | 277 (40)              | 64 (34) | 63 (46) | 44 (40) | 13 (39) | 2 (15) | 35 (45) | 1 (2) | 2 (13) | 30 (48) |
| Diabetes               | 121 (17)              | 29 (16) | 29 (21) | 20 (18) | 7 (21) | 0 | 18 (23) | 5 (8) | 3 (19) | 10 (16) |
| Other cancer           | 79 (11)               | 19 (10) | 14 (10) | 13 (12) | 1 (3) | 2 (15) | 16 (21) | 2 (3) | 1 (6) | 11 (17) |
| **Active antineoplastic treatment†** | % shown as proportion of all patients with that malignancy |         |         |         |         |         |         |         |         |         |         |
| Conventional chemotherapy‡ | 127 (18)              | 54 (29) | 29 (21) | 2 (2) | 9 (28) | 6 (50) | 1 (1) | 26 (42) | 0 | 0 |
| Low-intensity chemotherapy§ | 42 (6)               | 1 (1) | 4 (3) | 2 (2) | 0 | 1 (8) | 1 (1) | 0 | 2 (12) | 31 (49) |
| Molecular targeted therapies¶ | 82 (12)              | 7 (4) | 12 (9) | 28 (26) | 0 | 0 | 0 | 3 (5) | 14 (88) | 18 (29) |
| Monoclonal antibodies | 44 (6)                | 25 (13) | 14 (10) | 1 (1) | 4 (13) | 0 | 0 | 0 | 0 | 0 |
| Immunomodulatory drugs‖ | 45 (7)               | 0 | 45 (33) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypomethylating agents** | 33 (5)               | 1 (1) | 0 | 0 | 0 | 0 | 15 (19) | 17 (28) | 0 | 0 |
| Supportive care† † | 12 (2)               | 2 (1) | 0 | 0 | 0 | 0 | 5 (7) | 0 | 0 | 5 (8) |
| Not detailed           | 24 (3)               | 5 (2) | 6 (4) | 1 (1) | 5 (16) | 1 (8) | 2 (3) | 0 | 0 | 4 (6) |
| No active therapy      | 286 (41)             | 92 (49) | 27 (20) | 75 (69) | 14 (44) | 4 (33) | 54 (69) | 15 (25) | 0 | 5 (8) |
| **Care setting**       | % shown as proportion of all patients with that malignancy |         |         |         |         |         |         |         |         |         |         |
| Ambulatory             | 89 (13)              | 24 (13) | 16 (12) | 15 (14) | 4 (12) | 3 (23) | 6 (8) | 9 (15) | 6 (37) | 9 (14) |
| Hospital               | 608 (87)             | 163 (87) | 121 (88) | 97 (89) | 29 (88) | 10 (77) | 72 (92) | 52 (85) | 10 (63) | 54 (86) |
### Outcome

|                  | Survivors | Non-survivors |
|------------------|-----------|---------------|
|                  | 467 (67)  | 230 (33)      |
|                  | 128 (68)  | 59 (32)       |
|                  | 90 (66)   | 47 (34)       |
|                  | 70 (64)   | 39 (36)       |
|                  | 24 (73)   | 9 (27)        |
|                  | 11 (85)   | 2 (15)        |
|                  | 45 (58)   | 33 (42)       |
|                  | 34 (56)   | 27 (44)       |
|                  | 14 (87)   | 2 (13)        |
|                  | 51 (81)   | 12 (19)       |

Data are n (%) or median (IQR). Due to rounding, not all variables might add up to 100%.

ALL=acute lymphoid leukemia. AML=acute myeloid leukemia. CLL=chronic lymphocytic leukemia. CML=chronic myeloid leukemia. COVID-19=coronavirus disease 2019. HL=Hodgkin lymphoma. IQR=interquartile range. MDS=myelodysplastic syndrome. MM=multiple myeloma. NHL=non-Hodgkin lymphoma. Ph-MPN=Philadelphia chromosome-negative myeloproliferative neoplasms.

*Data missing for 7 patients. †Defined as having received anticancer therapy within 30 days prior to COVID-19 diagnosis; data missing for 2 patients. ‡Includes intensive and standard dosing. §Single-agent hydroxyurea, chlorambucil, or cyclophosphamide. ¶Includes tyrosine kinase inhibitors, Bruton’s tyrosine kinase inhibitors, Aurora kinase inhibitors, PI3K inhibitors, proteasome inhibitors, and histone deacetylase inhibitors. ¶¶Includes lenalidomide, pomalidomide, and thalidomide. **Includes azacitidine and decitabine. ††Includes transfusion and hematopoietic growth factor support.

---

**Table 2. Characteristics and outcomes of patients with hematologic malignancies and COVID-19, according to COVID-19 clinical severity**

COVID-19 severity classification followed WHO guidelines.(20) Severe disease was defined as: bilateral lung infiltrates on chest imaging that were not fully explained by congestive heart failure or other forms of volume overload; tachypnea (≥30 breaths/min); oxygen saturation ≤90% at rest; and/or PaO2/FIO2 ratio <300 mmHg. ‘Critical’ severity was defined as patients presenting with sepsis/septic shock, acute respiratory distress syndrome or multiple organ dysfunction/failure.
| Clinical severity of COVID-19 | Mild | Moderate | Severe | Critical |
|------------------------------|------|----------|--------|----------|
| n (%) shown as proportions of patients within a row/category |      |          |        |          |
| Total (n=692)*               | 104 (15) | 159 (23) | 290 (42) | 139 (20) |
| Age, years†                  |       |          |        |          |
| 18-49 (n=72)                 | 63 (50-73) | 71 (58-79) | 74 (66-81) | 72 (63-81) |
| 50-59 (n=93)                 | 23 (25)  | 27 (29)  | 28 (30) | 15 (16) |
| 60-69 (n=130)                | 19 (15)  | 27 (21)  | 51 (39) | 33 (25) |
| 70-79 (n=225)                | 23 (10)  | 50 (22)  | 110 (49) | 42 (19) |
| >80 (n=171)                  | 13 (8)   | 38 (22)  | 80 (47) | 40 (23) |
| Sex‡                        |       |          |        |          |
| Female (n=276)               | 41 (15) | 73 (26)  | 111 (40) | 51 (18) |
| Male (n=409)                 | 62 (15) | 83 (20)  | 178 (44) | 86 (21) |
| Comorbidities§, n            |       |          |        |          |
| 0 (n=133)                    | 40 (30) | 32 (24)  | 38 (29) | 23 (17) |
| 1 (n=180)                    | 24 (13) | 49 (27)  | 69 (38) | 38 (21) |
| 2 (n=152)                    | 17 (11) | 33 (22)  | 71 (47) | 31 (20) |
| ≥3 (n=192)                   | 17 (9)  | 34 (18)  | 98 (51) | 43 (22) |
| Hematologic malignancy       |       |          |        |          |
| Lymphoid malignancies (n=477)† | 75 (16) | 115 (24) | 196 (41) | 91 (19) |
| Non-Hodgkin lymphoma (n=187) | 33 (18) | 53 (28)  | 71 (38) | 30 (16) |
| Multiple myeloma (n=136)§    | 23 (17) | 32 (23)  | 61 (45) | 20 (15) |
| Chronic lymphocytic leukemia (n=109) | 9 (8) | 21 (19) | 47 (43) | 32 (29) |
| Hodgkin lymphoma (n=32)§     | 6 (19)  | 7 (22)   | 13 (41) | 6 (19)  |
| Acute lymphoid leukemia (n=13) | 4 (31) | 2 (15)   | 4 (31)  | 3 (23)  |
| Myeloid malignancies (acute/subacute) (n=139) | 17 (12) | 24 (17) | 62 (45) | 36 (26) |
| Acute myeloid leukemia (n=61) | 8 (13)  | 8 (13)   | 29 (48) | 16 (26) |
| Myelodysplastic syndrome (n=78) | 9 (12) | 16 (21) | 33 (42) | 20 (25) |
| Myeloproliferative malignancies (n=76)** | 12 (16) | 20 (26) | 32 (42) | 12 (16) |
| Chronic myeloid leukemia (n=16) | 4 (25) | 8 (50)   | 3 (19)  | 1 (6)   |
| Ph-negative myeloproliferative neoplasms (n=60)** | 8 (13) | 12 (20) | 29 (48) | 11 (18) |
| Hematopoietic stem cell transplantation†† |       |          |        |          |
| Autologous (n=51)            | 14 (27) | 15 (29)  | 16 (31) | 6 (12)  |
| Allogeneic (n=27)            | 9 (33)  | 4 (15)   | 6 (22)  | 8 (30)  |
| No (n=585)                   | 79 (14) | 134 (23) | 256 (44) | 116 (20) |
| Active antineoplastic treatment (n=691)†‡‡ |       |          |        |          |
| Conventional chemotherapy (n=127) | 22 (17) | 25 (20) | 54 (43) | 26 (20) |
Table 3. Prognostic factors of mortality in patients with hematologic malignancies and COVID-19 (n=697): time-to-event analysis.
| Pre-infection prognostic factors          | Unadjusted (univariable) | Partially adjusted* (partial multivariable) | Adjusted analysis (full multivariable model)† |
|------------------------------------------|--------------------------|---------------------------------------------|---------------------------------------------|
|                                          | HR (95%CI)                | HR (95%CI)                                  | HR (95%CI)                                 | P value |
| **Age, years**                           |                          |                                             |                                             |         |
| 18-49                                    | 1 (ref)                  | 1 (ref)                                     | 1 (ref)                                    | –       |
| 50-59                                    | 2.18 (0.85-5.56)         | 1.60 (0.61-4.23)                           | 1.79 (0.66-4.89)                           | 0.25    |
| 60-69                                    | 3.40 (1.43-8.12)         | 2.73 (1.12-6.66)                           | 3.17 (1.25-8.00)                           | 0.015   |
| 70-79                                    | 5.09 (2.22-11.7)         | 4.17 (1.78-9.79)                           | 5.20 (2.12-12.8)                           | <0.001  |
| ≥80                                      | 9.29 (4.07-21.2)         | 7.37 (3.12-17.4)                           | 10.1 (4.03-25.4)                           | <0.001  |
| **Sex**                                  |                          |                                             |                                             |         |
| Female                                   | 1 (ref)                  | 1 (ref)                                     | 1 (ref)                                    |         |
| Male                                     | 1.05 (0.81-1.37)         | 1.01 (0.77-1.33)                           | 1.13 (0.85-1.51)                           | 0.4     |
| **Comorbidities, n**                     |                          |                                             |                                             |         |
| 0                                        | 1 (ref)                  | 1 (ref)                                     | 1 (ref)                                    |         |
| 1                                        | 1.30 (0.82-2.06)         | 0.97 (0.60-1.56)                           | 0.99 (0.60-1.64)                           | 0.9     |
| 2                                        | 1.95 (1.25-3.04)         | 1.15 (0.72-1.84)                           | 1.17 (0.72-1.92)                           | 0.5     |
| ≥3                                       | 2.55 (1.67-3.88)         | 1.40 (0.89-2.20)                           | 1.51 (0.95-2.40)                           | 0.08    |
| **Hematologic malignancy**               |                          |                                             |                                             |         |
| Non-Hodgkin lymphoma                     | 1 (ref)                  | 1 (ref)                                     | 1 (ref)                                    |         |
| Multiple myeloma                         | 1.08 (0.74-1.59)         | 0.86 (0.58-1.27)                           | 0.80 (0.49-1.28)                           | 0.4     |
| Chronic lymphocytic leukemia             | 1.01 (0.74-1.65)         | 0.80 (0.52-1.24)                           | 0.92 (0.56-1.51)                           | 0.8     |
| Hodgkin lymphoma                         | 0.79 (0.39-1.60)         | 0.96 (0.47-1.96)                           | 1.20 (0.56-2.58)                           | 0.6     |
| Acute lymphoid leukemia                  | 0.43 (0.10-1.74)         | 1.02 (0.24-4.38)                           | 1.52 (0.36-6.58)                           | 0.6     |
| Acute myeloid leukemia                   | 1.39 (0.88-2.19)         | 1.47 (0.92-2.35)                           | 2.22 (1.31-3.74)                           | 0.003   |
| Myelodysplastic syndrome                 | 1.43 (0.93-2.19)         | 0.86 (0.52-1.24)                           | 1.14 (0.68-1.90)                           | 0.6     |
| Chronic myeloid leukemia                 | 0.32 (0.08-1.32)         | 0.33 (0.08-1.36)                           | 0.37 (0.08-1.70)                           | 0.20    |
| Ph-negative myeloproliferative neoplasms | 0.52 (0.28-0.97)         | 0.33 (0.17-0.64)                           | 0.33 (0.14-0.81)                           | 0.015   |
| **Hematopoietic stem cell transplantation** |                      |                                             |                                             |         |
| No                                       | 1 (ref)                  | 1 (ref)                                     | 1 (ref)                                    |         |
| Autologous                               | 0.45 (0.23-0.87)         | 0.90 (0.36-2.26)                           | 0.79 (0.31-2.07)                           | 0.6     |
| Allogeneic                               | 0.46 (0.19-1.11)         | 0.57 (0.28-1.19)                           | 0.56 (0.27-1.19)                           | 0.13    |
| **Active antineoplastic treatment§**     |                          |                                             |                                             |         |
| No active therapy                        | 1 (ref)                  | 1 (ref)                                     | 1 (ref)                                    |         |
| Conventional chemotherapy                | 1.04 (0.73-1.48)         | 1.56 (1.08-2.27)                           | 1.50 (0.99-2.29)                           | 0.05    |
| Low-intensity chemotherapy               | 0.50 (0.24-1.03)         | 0.46 (0.22-0.95)                           | 1.04 (0.43-2.50)                           | 0.9     |
| Molecular targeted therapy               | 0.74 (0.47-1.18)         | 0.74 (0.45-1.22)                           | 1.07 (0.61-1.88)                           | 0.8     |
| Monoclonal antibodies                    | 1.37 (0.83-2.28)         | 1.73 (1.02-2.93)                           | 2.02 (1.14-3.60)                           | 0.016   |
| Immunomodulatory drugs                   | 1.08 (0.64-1.84)         | 1.14 (0.66-1.98)                           | 1.64 (0.82-3.24)                           | 0.16    |
Hypomethylating agents | 1.03 (0.55-1.92) | 0.74 (0.45-1.22) | 0.47 (0.23-0.94) | 0.032  
Supportive care | 2.01 (0.93-4.33) | 1.15 (0.53-2.50) | 1.50 (0.66-3.40) | 0.3  
Not detailed | 0.88 (0.43-1.82) | 0.86 (0.40-1.86) | 0.86 (0.12-6.40) | 0.9

CI=confidence interval. COVID-19=coronavirus disease 2019. Ph-negative=Philadelphia chromosome-negative. Ref=reference group.

*Partial adjustment: multivariable analysis, all factors were adjusted by age, sex, and comorbidity count. †Full model: multivariable analysis, all variables were included in the model – including age, sex, comorbidity count, type of hematologic malignancy, and therapy. ‡HRs and 95% CI were estimated with Cox regression analyses. §Defined as having received anticancer therapy within 30 days prior to COVID-19 diagnosis

Table 4. COVID-19 pharmacological therapies and association with mortality in patients with hematologic malignancies and COVID-19, according to clinical severity of COVID-19: time-to-event analysis.
| Patients with data on clinical severity of COVID-19 | n (%) patients | n, events | Clinical severity of COVID-19 |
|--------------------------------------------------|----------------|-----------|----------------------------|
|                                                  |                |           | Mild/Moderate | Severe/Critical |
| Patients with data on clinical severity of COVID-19 | 692 (100)     | 227       | 263 patients; 15 events | 429 patients; 212 events |

### Analysis of association with mortality

| Univariable | Multivariable* |
|-------------|----------------|
| HR² (95% CI) | P value |
| HR² (95% CI) | P value |

**COVID-19 pharmacological therapy**

#### Antiviral therapy

| Drug | N (%) | n, events | Mild/Moderate | Severe/Critical |
|------|-------|-----------|---------------|-----------------|
| Hydroxychloroquine | 558 (81) | 184 | 0.92 (0.29-2.92) | 1.22 (0.33-4.56) | 0.8 | 0.40 (0.28-0.57) | 0.38 (0.27-0.56) | <0.001 |
| Azithromycin | 276 (40) | 90 | 1.25 (0.44-3.52) | 1.57 (0.54-4.56) | 0.6 | 0.69 (0.52-0.90) | 0.67 (0.58-0.89) | 0.006 |
| Antiretrovirals | 337 (49) | 116 | 1.16 (0.42-3.22) | 1.70 (0.57-5.04) | 0.4 | 0.77 (0.59-1.01) | 0.91 (0.69-1.20) | 0.5 |
| β-interferon | 50 (7) | 27 | 1.28 (0.17-9.78) | 2.12 (0.27-16.8) | 0.5 | 1.53 (1.01-2.32) | 1.52 (1.00-2.30) | 0.051 |

#### Antiviral combination therapy

| Therapy | N (%) | n, events | Mild/Moderate | Severe/Critical |
|---------|-------|-----------|---------------|-----------------|
| No therapy | 116 (17) | 33 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 |
| Hydroxychloroquine alone | 86 (12) | 34 | 1.11 (0.19-6.69) | 1.19 (0.16-6.60) | 0.8 | 0.72 (0.43-1.20) | 0.54 (0.31-0.92) | 0.024 |
| Hydroxychloroquine and azithromycin | 148 (21) | 40 | 0.66 (0.11-3.93) | 0.94 (0.13-7.11) | 0.6 | 0.35 (0.22-0.58) | 0.34 (0.21-0.57) | <0.001 |
| Hydroxychloroquine and antiretrovirals | 208 (30) | 68 | 1.02 (0.23-4.58) | 1.52 (0.27-8.63) | 0.9 | 0.43 (0.28-0.68) | 0.48 (0.30-0.77) | 0.002 |
| Hydroxychloroquine, azithromycin and antiretrovirals | 116 (17) | 42 | 1.80 (0.36-8.96) | 4.57 (0.70-29.7) | 0.14 | 0.40 (0.25-0.66) | 0.40 (0.24-0.67) | <0.001 |

#### Adjuvant therapy

| Therapy | N (%) | n, events | Mild/Moderate | Severe/Critical |
|---------|-------|-----------|---------------|-----------------|
| Systemic corticosteroids | 318 (46) | 133 | 2.43 (0.86-6.82) | 2.34 (0.80-6.76) | 0.13 | 0.88 (0.67-1.16) | 1.01 (0.76-1.35) | 0.9 |
| Tocilizumab | 132 (19) | 51 | 5.07 (1.61-15.9) | 5.94 (1.80-19.6) | 0.002 | 0.62 (0.45-0.86) | 0.87 (0.62-1.23) | 0.4 |

CI=confidence interval. COVID-19=coronavirus disease 2019. HR=hazard ratio.
*Multivariable analyses for the Mild/Moderate severity group are adjusted for age only, due to the limited number of events. †Multivariable analyses for the Severe/Critical severity group are adjusted for age (years), sex, and comorbidity count, except for the analysis of β-interferon, which was adjusted for age only. ‡HRs and 95% CI were estimated with Cox regression analyses.

**Figures**

![Flowchart diagram](image)

**Figure 1**

Patients with hematologic malignancies who were reported as having COVID-19 and who were included in the present analysis. Reporting hospitals included 22 of the 26 SERMAS regional health service centers (8/8 designated high complexity level hospitals; 10/12 intermediate complexity level; 4/6 low complexity level), and 5 of the 6 private centers.